Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.

Author: ArribasJosé Ramón, Arroyo-ManzanoDavid, DomingoPere, KnobelHernando, LlibreJosep M, MorenoSantiago, PodzamczerDaniel, RiveroAntonio, SaumoyMaria, TerrónAlberto

Paper Details 
Original Abstract of the Article :
To assess the efficacy and safety of maraviroc (MVC) administered once-daily in routine clinical practice. A retrospective multicenter study (27 centers in Spain) was conducted. Data were collected from the records of patients starting a regimen with MVC. Laboratory and clinical data were recorded e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1089/AID.2015.0386

データ提供:米国国立医学図書館(NLM)

Maraviroc Once-Daily: An Effective and Well-Tolerated Treatment Option for HIV

The field of [HIV treatment] continues to evolve, with researchers constantly seeking new and improved therapies. This study explored the effectiveness and safety of maraviroc (MVC) administered once-daily in routine clinical practice. The authors conducted a retrospective multicenter study involving a large number of patients, providing valuable insights into the real-world use of MVC. The results highlight MVC's potential as a viable treatment option for patients with HIV, particularly those who have previously been treated with other therapies.

Positive Outcomes with Once-Daily Maraviroc

A significant proportion of patients (73.3% at 12 months and 68.2% at 24 months) achieved viral suppression with MVC once-daily, demonstrating its effectiveness in controlling HIV infection. The study also showed that MVC was well-tolerated, with only a small number of patients experiencing adverse events. The authors concluded that MVC once-daily, combined with other antiretroviral agents, was a virologically effective and well-tolerated treatment option for a high percentage of pretreated patients.

HIV Treatment: A Balancing Act

HIV treatment is a complex process, and choosing the right therapy is crucial for optimal outcomes. This study provides evidence that MVC once-daily can be an effective and safe option for many patients. It is essential for clinicians to carefully consider the individual needs of their patients when selecting a treatment regimen. Just as a camel must navigate the challenges of the desert, individuals living with HIV face their own unique challenges. This research offers a glimmer of hope for a more manageable and effective HIV treatment landscape.

Dr.Camel's Conclusion

The study's findings are promising, demonstrating the potential of MVC once-daily as a viable treatment option for HIV. As a camel who has witnessed the transformative power of scientific progress, I am encouraged by the continued development of new and effective HIV therapies. Just as the desert transforms over time, the landscape of HIV treatment continues to evolve, offering hope for a healthier future.

Date :
  1. Date Completed 2017-12-18
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27250802

DOI: Digital Object Identifier

10.1089/AID.2015.0386

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.